What is Cognoptix?
Cognoptix is a pioneering medical technology firm dedicated to the early detection and diagnosis of Alzheimer's Disease through its innovative Sapphire II system. By utilizing a non-invasive eye scanning test, the company provides a scalable solution for physicians to monitor cognitive health, effectively bridging the gap between complex clinical diagnostics and routine patient care. Founded by Dr. Lee Goldstein and Dr. Leo Chylack, the organization operates at the intersection of biotechnology and neurology, focusing on high-impact interventions that improve patient outcomes. Their strategic focus involves forming deep alliances with pharmaceutical partners and academic institutions to validate their diagnostic platform for widespread clinical adoption.
How much funding has Cognoptix raised?
Cognoptix has raised a total of $42.1M across 6 funding rounds:
Series A
$1M
Series B
$18.5M
Series C
$4.6M
Debt
$390K
Series D
$15M
Other Financing Round
$2.6M
Series A (2007): $1M, investors not publicly disclosed
Series B (2008): $18.5M led by Inventages
Series C (2011): $4.6M, investors not publicly disclosed
Debt (2014): $390K featuring Inventages
Series D (2014): $15M backed by Launchpad Venture Group LLC, Inventages, and Alopexx
Other Financing Round (2020): $2.6M with participation from New York Angels Inc, Launchpad Venture Group LLC, and Harvard Business School Alumni Angels of Greater New York
Key Investors in Cognoptix
Inventages
Inventages is a prominent global venture capital firm specializing in life sciences, nutrition, and wellness, providing strategic support and financial expertise to high-growth healthcare companies.
Launchpad Venture Group LLC
Launchpad Venture Group is a New England-based angel network that provides both financial capital and mentorship to early-stage technology and science-driven startups.
Alopexx
Alopexx is a clinical-stage biotechnology company based in Massachusetts that focuses on developing immune-mediated therapeutics for a variety of microbial infections.
What's next for Cognoptix?
With the recent strategic investment, Cognoptix is well-positioned to accelerate its clinical validation efforts and expand its footprint within the global diagnostic market. The company's forward-looking strategy centers on the commercialization of the Sapphire II system, aiming to integrate its technology into standard neurological assessment protocols. By prioritizing partnerships with major pharmaceutical entities, Cognoptix intends to leverage its diagnostic data to support broader therapeutic research initiatives. As the company moves toward broader market entry, the focus will remain on scaling operational capacity and ensuring the regulatory compliance necessary for global deployment in doctor's offices and specialized memory clinics.
See full Cognoptix company page
